NEW YORK, Sept. 4, 2025 — Billy Bets, the AI-powered sports-betting startup, closed a $1 million pre-seed round with Coinbase Ventures, and participation from Virtuals Ventures, Contango Digital, CMS Holdings, and a roster of athlete and crypto-native angels. The capital accelerates the public launch of the Billy Terminal, personalized autonomous betting agents, and expanded $BILLY token utility.

Sports wagering generates an estimated $250 billion in annual handle, yet fewer than 1% of bets are executed by AI agents on prediction markets. “That inefficiency is our wedge,” said Joe O’Rourke, Co-founder & CEO. “AI agents have already changed investing; now they’re coming for sportsbooks. Billy Bets will turn that small sliver into the default way fans bet.”

Built on Base (Coinbase‘s Layer 2), Billy supports bet discovery across prediction markets, including Kalshi and Polymarket, by highlighting edges, routes wagers to the best available price, and enables customized automated strategies. Billy’s natural-language terminal turns “Show me plus-EV NFL props tonight” into live odds, automated execution and real-time, traceable ROI tracking. Billy has routed over $1 million in betting volume, growing at 23% per week, since the launch of the Billy Terminal in June.

“Fundamentally, we believe all sports bettors will eventually rely on AI to improve their chances, particularly so with the advent of prediction markets, and we aim to be the best supplier of that agentic technology,” added Jared Augustine, Co-founder & Executive Chairman.

About Billy Bets

Billy Bets is an AI built for sports prediction markets, designed to upend the $250B sports gaming industry. Using proprietary machine learning models and big data, Billy analyzes prediction markets and betting exchanges in real time to surface the best opportunities at the best prices. Users can follow individual predictions or apply one of Billy’s automated strategies across their favorite sports and events—executing bets directly from their wallet in just one click. The Billy ecosystem is powered by the $BILLY utility token, which unlocks staking rewards, loyalty incentives, and exclusive access. Founded by multi-exit entrepreneurs Jared Augustine and Joe O’Rourke, Billy recently closed a $1m pre-seed round led by Coinbase Ventures. Learn more at billybets.ai and follow @askbillybets & @billybets_ai.

SOURCE Billy Bets

Funding round led by Dimension Capital, with participation from Stage 2 Capital, Flybridge Capital Partners, Ridge Ventures, Tokyo Black Venture Capital, and Vermillion Cliffs, along with several notable angel investors.

PORTLAND, Ore., Sept. 4, 2025 — Fiveonefour, a leader in data and analytics AI and developer tooling, today announced it has raised $17 million in total funding. The funding will be used to accelerate AI agent development, expand support for enterprise customers, deepen technical partnerships, and invest in growing their open source community.

As AI agents accelerate in adoption, enterprises face mounting pressure to modernize their data infrastructure to support real-time analytics and intelligent features. IDC reports that AI-enabling tech spend will hit $337 billion this year, with most Global 2000 companies adopting high-performance data systems by 2027. Fiveonefour enables developer teams to quickly and effectively deliver the specialized analytical infrastructure needed to power AI insights at conversation speed. For example, F45 Training — a Fiveonefour customer — powers its Lionheart biometric analytics feature with the platform, which delivers real-time performance insights and personalized workout feedback. Members who engage with Lionheart are 2.5X more valuable than average, making them F45’s most loyal and engaged users.

“Modern analytical use cases need more than a classic data warehouse with some dashboards,” said Tim Delisle, CEO and Co-Founder of Fiveonefour and former VP of Engineering at Nike. “AI agents and custom applications demand flexible, performant infrastructure coupled with developer and AI-friendly software interfaces like APIs and MCPs. We believe the future of data and analytics depends on the core developer experience for humans and AI agents alike, and this capital helps us deliver on that mission.”

At the heart of Fiveonefour’s offering is the Moose Stack, a fast-growing, open-source developer toolkit in TypeScript and Python, designed for developers building analytical backends. By abstracting away the complexity of data infrastructure, the Moose Stack enables software teams to rapidly integrate AI-ready analytics and operational data capabilities directly into their applications. Momentum has exploded, with installs doubling month over month, and enterprises across healthcare, manufacturing, and connected fitness are already using the Moose Stack to power user-facing analytics and AI-enabled data systems.

“In a world of AI hype, Fiveonefour is unlocking one of the biggest challenges in the enterprise today: developing and leveraging a solid data foundation to solve real problems with AI,” said Nan Li, Founder and Managing Partner at Dimension Capital. “With its open source core and  focus on the developer, Fiveonefour is uniquely positioned to push data and analytics into the bright AI future.”

Fiveonefour’s full product suite – including Boreal, a fully managed cloud infrastructure platform, and Sloan, AI agents and tooling for data & analytics – makes it simple for human and agentic developers to adopt and integrate specialized analytical infrastructure into their existing applications. Current technical partners and supported technologies include ClickHouse, Kafka, RedPanda, Temporal, and Redis. With this new funding, growing enterprise adoption, and a thriving open source community, Fiveonefour is scaling to become a cornerstone of the modern AI and analytics stack for developers. To learn more about Fiveonefour, please visit fiveonefour.com

About Fiveonefour:

Fiveonefour is on a mission to bring world-class AI and developer experiences to data and analytics. Fiveonefour’s developer toolkit for analytical backends offers open source frameworks, tooling, and AI for human and agentic developers. Through the open-source Moose Stack, Boreal cloud platform, and Sloan AI agents, Fiveonefour enables developers to quickly leverage the latest and greatest specialized analytical infrastructure to power user-facing analytics and custom operational data warehouses. Founded in 2023 by former Nike executives and serial entrepreneurs, the company is backed by Dimension Capital, Stage 2 Capital, Flybridge Capital Partners, Ridge Ventures, Tokyo Black Venture Capital, and Vermillion Cliffs, along with several notable angel investors.

SOURCE Fiveonefour Labs, Inc.

SAN FRANCISCO, Sept. 4, 2025 — Juniper Square, a fund operations partner to more than 2,000 private markets GPs, today announced a strategic investment from Nasdaq Ventures to further accelerate innovation in private markets technology. In addition to the investment, Nasdaq (Nasdaq: NDAQ) and Juniper Square will establish a partnership which will explore ways to advance the development of integrated data and liquidity solutions for private fund managers. The news of this investment and partnership follows the company’s $130 million Series D financing announced in June.

“For over a decade, Juniper Square has been focused on helping GPs build enduring firms,” said Alex Robinson, CEO and Co-Founder at Juniper Square. “Nasdaq shares our vision for more efficient and transparent private markets. Together, we can combine world-class data with purpose-built software to deliver the go-to platform for raising and managing private capital.”

As private market investment continues to accelerate, next-generation data solutions that enhance GP visibility and turbocharge their fundraising efforts are a must for GPs. Juniper Square and Nasdaq will collaborate on new opportunities to deliver the tools critical to a modern GP enterprise and improve private market liquidity, including through innovations in secondaries.

“Private markets are experiencing a generational shift and real-time, data-driven insights are becoming essential to how firms raise and deploy capital,” said Gary Offner, Senior Vice President, Head of Nasdaq Ventures at Nasdaq. “Juniper Square provides an innovative platform to support fund operations for GPs, and we’re proud to invest in their vision.”

This investment and collaboration mark a significant step in Juniper Square’s efforts to deliver AI-powered solutions, integrated services, and industry-specific infrastructure to the global private markets.

For more about Juniper Square, visit here.

About Juniper Square
Juniper Square is the fund operations partner to more than 2,000 private markets GPs worldwide. Our unified platform connects software, data, and fund administration services to help firms scale faster, streamline operations, and enhance the investor experience. Juniper Square’s technology brings LPs and GPs together and powers everything from fundraising and onboarding to treasury, reporting, and business intelligence. Today, more than 40,000 funds, 650,000 LP accounts, and $1 trillion in LP capital are managed through Juniper Square.

About Nasdaq Ventures
Launched in 2017, Nasdaq Ventures is the global venture investing program of Nasdaq, Inc. (Nasdaq: NDAQ). Focused on cultivating technology advancement within financial services, Nasdaq Ventures invests in companies driving innovation in market infrastructure, data, analytics & workflow technologies, anti-financial crime, digital assets, ESG, and emerging asset classes. To learn more, visit: www.nasdaq.com/nasdaq-ventures. 

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

SOURCE Juniper Square

BOSTON, Sept. 4, 2025 — Nanoramic, Inc. (“Nanoramic”) a pioneer in advanced batteries, today announced it has secured a strategic equity investment from ITOCHU Corporation (“ITOCHU”), with additional participation from existing investor Top Material. The financing will be used to accelerate the global commercialization of Nanoramic’s Neocarbonix® battery technology and products and will significantly strengthen its global supply chain in response to growing customer demand.

Neocarbonix® is a force multiplier for the battery industry, designed to drop into existing manufacturing lines and deliver far-reaching improvements in battery cost, energy density, power, and fast-charging performance.

The investment follows a period of significant momentum for Nanoramic, including a $44 million funding round co-led by General Motors Ventures and Catalus Capital, with participation from Samsung Ventures, and the grand opening of its new 40,000-square-foot headquarters in Woburn, Massachusetts. The company has recently commenced commercial shipments of Neocarbonix from the new facility, marking its transition to the next phase of global growth and commercial adoption.

The strategic partnership with ITOCHU will help catalyze the global adoption of Neocarbonix. This collaboration forms a powerful synergy between Nanoramic’s battery technology leadership and ITOCHU’s world-class expertise in logistics and supply chain management. ITOCHU will serve as a pivotal logistics partner, while Top Material continues to provide world-class infrastructure as a key scale-up partner. Together, they create a robust, de-risked global supply chain for customers adopting Neocarbonix.

“This strategic investment from ITOCHU and Top Material is a testament to our significant commercial momentum and the transformative potential of Neocarbonix,” said John Cooley, Founder and CEO of Nanoramic. “These partnerships provide a direct solution to the supply chain challenges of global expansion. By integrating with ITOCHU’s world-class logistics network and Top Material’s manufacturing excellence, we are not only scaling our reach but also offering our customers a reliable path to adopt our technology with confidence. We are thrilled to welcome ITOCHU and are grateful for the continued support from investors like Top Material as we enter this exciting new phase of growth.”

About Nanoramic, Inc.
Founded in 2009 out of MIT, Nanoramic, Inc. is an industry-leading energy storage and advanced materials company that has developed an innovative electrode technology, Neocarbonix®. Nanoramic is commercializing Neocarbonix to transform energy storage for all battery applications: increasing energy density and longevity, while reducing costs and improving sustainability. Nanoramic works with some of the world’s largest automakers, consumer electronics companies, and battery manufacturers to develop and commercialize batteries made with Neocarbonix. Nanoramic, Inc. is the exclusive designer, manufacturer, and licensor of Neocarbonix and Fastcap® Ultracapacitors. Visit www.nanoramic.com.

About ITOCHU Corporation
The history of ITOCHU Corporation dates back to 1858 when the Company’s founder Chubei Itoh commenced linen trading operations. Since then, ITOCHU has evolved and grown over 160 years. With approximately 90 bases in 61 countries, ITOCHU, one of the leading sogo shosha, is engaging in domestic trading, import/export, and overseas trading of various products such as textile, machinery, metals, minerals, energy, chemicals, food, general products, realty, information and communications technology, and finance, as well as business investment in Japan and overseas.

SOURCE Nanoramic, Inc.

Specifically, proceeds from the round will be used to establish a state-of-the-art research laboratory and factory in Asia, enabling rapid prototyping and scaling of LifeLabs’ proprietary textile technologies.

“This funding marks a pivotal step forward in our mission to transform textiles into powerful climate solutions,” said Sophia Ou, CEO and co-founder of YiLab. “The enthusiasm from investors reinforces both the urgency of our work and the strength of our technology. With our new R&D lab and factory, we’re building a fast process from laboratory technology innovation to real-world impact.”

LifeLabs is known for its thermoregulating textiles requiring fewer resources for production while delivering unmatched comfort and energy efficiency to the wearer. The breakthrough fabric technology, which originated at Stanford University a decade ago and has since proven in commercial space, provide scalable solutions to lower global energy consumption and carbon emissions.

The pre-A round attracted a diverse group of investors from technology, sustainability, and consumer sectors, reflecting the broad applicability and market demand for LifeLabs’ technologies.

Today, Lifelabs is working with established global apparel and accessory brands on future season launches.

About YiLab Temperature Control Technologies
YiLab Temperature Control Technologies is a materials science company founded in 2024 by Professor Yi Cui at Stanford University and Ms Sophia Ou. YiLab develops and commercializes advanced thermoregulating fabrics that enhance comfort while reducing global energy consumption and carbon emissions. The technology comes from LifeLabs Design. For more information, visit www.lifelabs.design.

Media Contacts:
Annie Armstrong, [email protected]
Ben Ryan, [email protected]

SOURCE YiLab Temperature Control Technologies / LifeLabs Design

The move reflects Alpha’s commitment to building on its collaborative growth equity model in global tech hubs like Israel.

NEW YORK, Sept. 4, 2025 — Alpha Partners, a leading growth equity firm that invests in growth rounds led by the world’s best investors, today announced the appointment of Gal Gitter as a Partner. Gitter will be based in Tel Aviv and will lead Alpha’s efforts to bring its collaborative growth equity model to Israel.

The appointment reflects Alpha’s view that Israel remains one of the world’s most important technology ecosystems. The firm’s model—designed to partner with early-stage venture funds rather than compete against them—helps early investors double down on their best-performing companies at the growth stage by supplying capital through pro-rata rights.

This approach has powered Alpha’s investments in globally recognized businesses such as Coupang, Careem, Chainguard, Apptronik, Socure, and Baseten.

“Today, Alpha sees about half of the U.S.’s growth rounds per year and, with our VC partners, has the ability to invest in about a quarter of these deals,” said Steve Brotman, Managing Partner of Alpha Partners. “Our pioneering VC partnership model enables us to invest in what we believe to be the most promising companies globally at the growth stage, typically investing alongside the top VCs in the world. Historically, Israeli-founded companies account for 1 in 6 U.S. tech unicorns. As such, we are excited to formally launch our model in Israel, as we believe the country will continue generating some of the world’s most important tech companies.”

Gitter was formerly Head of Ibex’s Israel Growth Fund and a leader within McKinsey’s Corporate Development Group. His experience spans investment and operational roles across Israeli startups and global investors.

“Alpha is one of the few firms purpose-built to collaborate with other funds rather than compete with them,” said Gitter. “That ethos resonates in Israel, where early investors play a central role in helping companies launch but often can’t continue participating as those companies scale. By bringing Alpha’s model to Israel, we can empower early stage investors to continue their partnership with their portfolios’ top performers at the growth stages.”

Alpha has already completed multiple Israeli founded investments leveraging its partnership model, including in cybersecurity companies Semperis and Zero Networks, underground mapping leader Exodigo and AI/Healthtech player Vi Labs. The fund’s Israel operations are co-led by Steve Brotman and Gal Gitter, with Charlie Federman serving as a Venture Partner and Lior Avisar serving as a Venture Investor.

About Alpha Partners
Alpha Partners is a $400 million AUM growth equity firm that invests alongside early-stage venture capital firms in their highest-performing companies. Over the past 12 years, the firm has pioneered the model of partnering with early investors to leverage their pro-rata rights, providing the capital needed to maintain its VC partner’s ownership and support continued involvement in their portfolio companies. Alpha has relationships with nearly half of all U.S. and Israeli headquartered VCs, over 1,000 venture capital firms that are invested in nearly 4 in 5 technology companies. Alpha has invested in more than 30 growth-stage companies worldwide. The portfolio companies identified and described herein do not represent all of the portfolio companies purchased, sold or recommended for funds advised by Alpha Partners. AUM indicated is as of September 2025. Certain information contained herein may constitute “forward-looking statements and are based on information presently available to Alpha. Due to various risks and uncertainties, actual events or results may differ materially from those reflected or contemplated in such forward-looking statements. This press release is not a solicitation of an offer to purchase securities and may not be relied upon in connection with the purchase or sale of any security. Learn more at alphapartners.com

SOURCE Alpha Partners

LOUVAIN-LA-NEUVE, Belgium, Sept. 4, 2025 — One2Treat SA, a fast-growing technology company transforming how the patient voice is integrated into clinical development, announced today the successful completion of a planned seed extension to accelerate its software platform development.

In parallel, One2Treat has relocated to a larger office in Louvain-la-Neuve to support its continued growth.

Shareholder confidence accelerates One2Treat’s investment in software platform development.

The conclusion of One2Treat’s planned seed extension funding round marks a key milestone in the company’s growth. This investment follows the successful deployment of the One2Treat Insights^® module across multiple live projects and the recent release of the One2Treat Voice^® module. It reflects the confidence of initial shareholders in One2Treat’s unique approach to answer the growing needs of the biopharma industry to both increase productivity and better reflect what matters to patients and clinicians.

The funding supports the continued development and scaling of One2Treat’s cloud-based software platform. This platform integrates diverse patient-focused outcomes into a single, comprehensive assessment of treatment effects, enabling a clearer understanding of the Net Treatment Benefit. The platform answers strategic needs for clinical development decisions, but also supports the overall medical value of a new treatment during regulatory discussions, HTA and commercialization.

“Based on multiple recent successes, our shareholders were keen to accelerate the investment in our platform development. In addition, we offered every employee the opportunity to become a shareholder, and all chose to take part, highlighting a deep, shared commitment to our mission of putting patient voices at the center of clinical research.” — Sébastien Coppe, CEO, One2Treat

Move to larger office supports One2Treat’s planned team expansion

Alongside the capital increase, One2Treat has moved to a new office in Louvain-la-Neuve, a dynamic academic and tech ecosystem just outside Brussels.

“The new space provides a larger, more modern and collaborative environment for the expanding team, fostering innovation and facilitating closer partnerships with key academic and industry stakeholders.” – Marc Buyse, Founder One2Treat

About One2Treat

One2Treat is dedicated to transforming the way biopharmaceutical companies design, analyze and interpret randomized clinical trials, and how the overall medical value of a treatment may be communicated. Through its innovative software platform and patient-centered methodologies, One2Treat helps sponsors incorporate the patient’s voice into early trial design, endpoint selection, and treatment value assessment. By aligning clinical evidence generation with patients and clinicians’ needs, One2Treat supports more meaningful clinical trials, efficient decision making and enhanced regulatory discussions, leading to faster market access.

For more information about One2Treat and its innovative approach to clinical trial design and market access, please visit: www.one2treat.com.

SOURCE One2Treat

PITTSBURGH, Sept. 4, 2025 — Pointsville, a pioneering platform for digital asset infrastructure and loyalty, today announced the successful completion of its Series A funding round led by Valor Capital Group, with participation from an exceptional group of global investors and industry leaders. Backers include Tether, Itaú Unibanco’s founding family, Nubank’s co-founder, Temasek-backed Superscrypt, SNZ, Credit Saison, K2 Integrity, Citrino, and Dynamo‘s partners.

The round unites a uniquely powerful coalition: the world’s leading stablecoin operator, Latin America’s largest banks, Asia’s leading financial services firms, and globally recognized risk, intelligence, and financial firms. Together, they bring unparalleled reach and expertise to accelerate Pointsville’s mission of bridging traditional assets with next-generation digital asset infrastructure. With the tokenized real-world asset (RWA) market projected to exceed $10 trillion by 2030, we are leading this transformation by setting the standard for how traditional assets move into digital markets.

The steady maturation of the digital asset ecosystem has fueled unprecedented demand for the tokenization of real-world assets (RWA). Existing infrastructure has fallen short, fragmenting assets, data, and liquidity across traditional and onchain finance. Pointsville fills this gap with purpose-built tokenization infrastructure, shaped by the founders’ firsthand experience bridging institutional finance and digital assets.

As part of the financing, Bruno Batavia, Principal and Director of Emerging Tech at Valor Capital Group, has joined Pointsville’s Board of Directors. Batavia previously served more than a decade at Brazil’s Central Bank, where he played a key role in launching the Digital Real (DREX) initiative and led the Tokenization Working Group, shaping how central banks implement tokenized asset infrastructure globally.

Gabor Gurbacs, Founder and CEO of Pointsville: “Pointsville is built for the next era of market infrastructure where real-world assets converge with digital networks in an open, borderless global marketplace. This round brings us extraordinary partners whose reach and expertise will accelerate that vision and transformation worldwide.”

Ricardo Villela Marino, Vice Chairman of Itaú: “Ricardo Villela Marino, Vice Chairman of Itaú Unibanco, commented:

“While I serve as Vice Chairman of Itaú, I want to emphasize that my support for Pointsville is a personal investment, independent from the bank. I believe the company is addressing one of the most important frontiers in global finance: building the infrastructure that will allow real-world assets to move seamlessly into digital markets. Pointsville has the vision and capability to shape how this sector evolves, and I am excited to support their journey as they help set the standards for the next era of market infrastructure.”

Paolo Ardoino, CEO of Tether: “Tokenization is rapidly emerging as one of the most practical and impactful drivers of real-world asset adoption. Hadron by Tether is proud to support this transformation, collaborating with Pointsville’s experienced team to deliver the scale and usability required to integrate real-world assets and loyalty programs into the digital economy.”

Bruno Batavia, Valor Capital Group: “Pointsville represents the kind of breakthrough platform we want to support—one with the potential to transform financial infrastructure across regions and asset classes through tokenization as we move toward truly global capital markets on blockchain rails. We are excited to partner with Gabor and his team to scale this opportunity.”

The Series A closing coincides with the rollout and expansion of major Pointsville-powered initiatives, including serving as the core technology provider for Hadron by Tether and powering new loyalty and experiences, such as the Fanatics FanCash program, and advancing projects with leading institutions and governments. Proceeds will accelerate product development, expand partnerships, and scale infrastructure to meet global demand.

Learn more at pointsville.com.

Media Contact (Media Only):

Alexandre Lores
Email: [email protected] 

SOURCE Pointsville

CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity;
CTA to be filed in 2H 2025

MONTREAL, Sept. 4, 2025 — Congruence, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d) genetic obesity, GBA1-driven Parkinson’s disease and Alpha-1 antitrypsin (A1AT) deficiency, announced today the closing of a US $32 million financing round.

The round included participation from all existing investors including: Amplitude Ventures, FSTQ, Lumira, Investissement Quebec, BDC Capital’s Thrive Venture Fund, OrbiMed, Driehaus, Silver Arc, and Alexandria.

“This financing enables us to generate the first clinical proof of concept data with our corrector for MC4R-d driven obesity, a serious and debilitating condition without current treatment options,” commented Dr. Clarissa Desjardins, CEO of Congruence. “We will also advance our programs in GBA-1 Parkinson’s Disease and Alpha-1 Antitrypsin Deficiency toward Development Candidate nomination this year.”

Congruence plans to start a Phase 1 trial of CGX-926 in healthy volunteers, including a Phase 1b efficacy cohort in MC4R-d patients, in early 2026. Congruence will also advance its programs targeting Parkinson’s Disease and A1AT-deficiency into late preclinical testing.

“Congruence is building a transformative pipeline of drugs it has discovered leveraging its powerful computational engine, Revenir™. The team has demonstrated scientific rigor and capital efficiency in advancing these important medicines into late preclinical testing,” commented Daniel Hétu, M.D., MBA, Managing Director at Lumira Ventures. “We are proud to continue to support Congruence as it advances its lead program CGX-926 into clinical testing and inches closer towards its mission of treating diseases of high unmet medical need.”

The Company also continues to advance its R&D collaborations, including a multi-target deal in oncology with Ono Pharmaceuticals and another collaboration on a difficult to drug metabolic target with an undisclosed pharmaceutical company.

“Too many patients with devastating genetic conditions have been left without effective treatments. Congruence’s small-molecule corrector approach offers new hope for people affected by MC4R-driven obesity, GBA Parkinson’s, A1AT deficiency and cancer.  We are honored to support their mission through our investment in Congruence,” added Nancy Harrison, Venture Partner at Amplitude Ventures.

About Revenir™ Drug Discovery Platform

Revenir™, Congruence’s proprietary computational drug discovery platform, captures the dynamic biophysical changes caused by mutations in proteins, offering unique insights into protein defects and their correction. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, Revenir™ predicts small molecule induced correction of the underlying pathogenic defect in proteins.

About Congruence Therapeutics

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson’s Disease, and α1-Antitrypsin Deficiency. Congruence is further deploying its discovery platform to support two multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors for the treatment of solid tumors and metabolic diseases.

For more information, please visit www.congruencetx.com.

Company Contact
Charles Grubsztajn
Chief Operating Officer
[email protected]

Media Contact
Amy Conrad
Juniper Point
[email protected] 
858-366-3243

SOURCE Congruence Therapeutics